Paclitaxel and carboplatin in bladder cancer
2000; Elsevier BV; Volume: 36; Linguagem: Inglês
10.1016/s0959-8049(00)00076-9
ISSN1879-0852
Autores Tópico(s)Renal cell carcinoma treatment
ResumoPaclitaxel demonstrates significant single-agent activity in advanced urothelial carcinoma. Paclitaxel/carboplatin is an active and tolerable outpatient chemotherapy treatment regimen for these patients. This regimen has been studied in several phase II trials with response rates ranging from 14 to 65%. Paclitaxel/carboplatin may be considered in patients with advanced urothelial cancer and renal insufficiency, and a recent Eastern Cooperative Oncology Group (ECOG) phase II trial investigates this regimen specifically in this patient population. Ongoing ECOG trials are comparing paclitaxel/carboplatin with M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) in both the advanced disease and adjuvant settings.
Referência(s)